Novel drugs and intervention strategies for the treatment of chronic kidney disease

摘要: Chronic kidney disease (CKD) is a worldwide health problem. The most often progressive of nature with high impact on patients and society. It increasingly recognized that CKD can be detected in the early stages should managed as possible. Treatment cause, but particular control main risk markers, such blood pressure, glucose albuminuria, has been instrumental delaying progression to end-stage renal (ESRD). However, despite state art therapy, absolute cardiovascular morbidity mortality remains devastatingly high. Novel drugs are therefore highly desirable halt effectively (and cardiovascular) function loss. Recently, several novel strategies have tested targeting traditional factors pressure (combination therapy angiotensin converting enzyme inhibitors (ACEi) receptor blockers (ARB) mineralocorticoid antagonists) well dyslipidaemia (statins) surprising results. In addition, drug targets specifically related kidney, vitamin D, uric acid, erythropoietin phosphate, subject clinical trials, some instances unexpected Finally, including endothelin receptors inflammatory pathways explored potential avenues improve protection, albeit not unequivocally successful. this article we review or intervention for management CKD, try provide explanations failure promising hypothesize success new strategies.